TY - JOUR
T1 - Antibiotic-nanomedicines
T2 - Facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections
AU - Ritsema, Jeffrey A.S.
AU - Van Der Weide, Hessel
AU - Te Welscher, Yvonne M.
AU - Goessens, Wil H.F.
AU - Van Nostrum, Cornelus F.
AU - Storm, Gert
AU - Bakker-Woudenberg, Irma A.J.M.
AU - Hays, John P.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.
AB - Respiratory tract infections are one of the most frequent infections worldwide, with an increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved treatment requires the development of new therapeutic strategies, including the possible development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment or conjugation and can be administered via aerosolization. The efficacy and tolerability of this approach has been shown in clinical studies, with amikacin liposome inhalation suspension being the first inhalatory antibiotic-nanomedicine approved by the US FDA. In this special report, we summarize and discuss the potential value and the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) respiratory tract infections.
KW - aerosols
KW - antibiotic nanomedicines
KW - antibiotic resistance
KW - pulmonary administration
KW - respiratory tract infections
UR - http://www.scopus.com/inward/record.url?scp=85058010048&partnerID=8YFLogxK
U2 - 10.2217/fmb-2018-0194
DO - 10.2217/fmb-2018-0194
M3 - Article
C2 - 30499686
AN - SCOPUS:85058010048
SN - 1746-0913
VL - 13
SP - 1683
EP - 1692
JO - Future microbiology
JF - Future microbiology
IS - 15
ER -